Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of semaglutide injection versus Wegovy for weight management in adults with obesity
CTR20244841Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, body weight control, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Mar 2025; status: completed.
02
Drugs
03
Conditions
obesitybody weight control
Beyond the preview
Go deeper on CTR20244841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244841.